Saffron for COVID-19-related cytokine storm: Hype or hope? A mini-review of current evidence.

Alexios-Fotios A Mentis, Maria Dalamaga, Cuncun Lu, Moschos G Polissiou
Author Information
  1. Alexios-Fotios A Mentis: University Research Institute of Maternal and Child Health & Precision Medicine, Athens, Greece.
  2. Maria Dalamaga: Department of Biological Chemistry, School of Medicine, National and Kapodistrian University of Athens, 75 Mikras Asias, 11527, Athens, Greece.
  3. Cuncun Lu: Evidence-Based Medicine Center, School of Basic Medical Sciences, Lanzhou University, Lanzhou, China.
  4. Moschos G Polissiou: Laboratory of Chemistry, Department of Food Science and Human Nutrition, School of Food, Biotechnology and Development, Agricultural University of Athens, Athens, Greece.

Abstract

AIM: To assess the potential role of saffron in downregulating inflammation and cytokine storm during COVID-19.
MAIN FINDINGS: Three main compounds of saffron, i.e., crocetin esters, picrocrocin, and safranal, present strong antioxidant and anti-inflammatory action for several disease states (e.g., Alzheimer's, cancer, and depression) but have also been studied in COVID-19. In particular, based on our comprehensive review of both and studies, saffron's essential oils and other constituents appear to have both immunomodulatory and anti-asthmatic actions; these actions can be particularly helpful to treat patients with respiratory symptoms due to COVID-19. Moreover, crocin appears to reduce the COVID-19-related cytokine cascade and downregulate angiotensin-converting enzyme 2 () gene expression. Last, studies suggest that saffron's astragalin and crocin could have inhibitory actions on SARS-CoV-2 protease and spike protein, respectively.
CONCLUSION: Saffron represents a promising substance for toning down cytokine storm during COVID-19, as well as a potential preventive treatment for COVID-19. However, appropriate randomized clinical trials, especially those using biomarkers as surrogates to assess inflammatory status, should be designed in order to assess the clinical efficacy of saffron and allow its use as an adjunct treatment modality, particularly in resource-poor settings where access to drugs may be limited.

Keywords

References

  1. J Biomol Struct Dyn. 2022 Oct;40(16):7408-7423 [PMID: 33685364]
  2. Intensive Care Med. 2020 Nov;46(11):2067-2070 [PMID: 33026460]
  3. J Biomol Struct Dyn. 2021 May;39(8):2971-2979 [PMID: 32306860]
  4. Metabol Open. 2020 Dec;8:100066 [PMID: 33205039]
  5. Transl Psychiatry. 2021 Feb 18;11(1):130 [PMID: 33602896]
  6. Caspian J Intern Med. 2020 Fall;11(Suppl 1):466-478 [PMID: 33425263]
  7. J Biochem Mol Toxicol. 2019 Dec;33(12):e22410 [PMID: 31617649]
  8. BMJ. 2020 Jul 30;370:m2980 [PMID: 32732190]
  9. BMC Med. 2021 Apr 29;19(1):107 [PMID: 33910589]
  10. Cell. 2021 Jul 22;184(15):3949-3961.e11 [PMID: 34161776]
  11. Phytomedicine. 2021 Oct;91:153699 [PMID: 34419735]
  12. Front Pharmacol. 2020 Nov 25;11:571434 [PMID: 33324206]
  13. Heliyon. 2021 May;7(5):e07068 [PMID: 34007917]
  14. Sci Total Environ. 2020 Aug 1;728:138859 [PMID: 32334163]
  15. Front Pharmacol. 2019 Nov 01;10:1281 [PMID: 31736758]
  16. Phytother Res. 2020 Nov;34(11):2911-2920 [PMID: 32430996]
  17. Heliyon. 2020 Dec;6(12):e05681 [PMID: 33344790]
  18. Adv Nutr. 2019 Mar 1;10(2):185-195 [PMID: 30615051]
  19. Genome Res. 2018 Sep;28(9):1272-1284 [PMID: 30097539]
  20. J Food Biochem. 2021 May;45(5):e13718 [PMID: 33817822]
  21. J Agric Food Chem. 2006 Nov 15;54(23):8762-8 [PMID: 17090119]
  22. Drug Dev Res. 2021 Nov;82(7):883-895 [PMID: 33817811]
  23. Front Neurosci. 2019 Mar 26;13:249 [PMID: 30971876]
  24. Sci Rep. 2020 Oct 23;10(1):18150 [PMID: 33097779]
  25. DNA Cell Biol. 2008 Dec;27(12):657-64 [PMID: 18788978]
  26. J Agric Food Chem. 2015 Oct 7;63(39):8662-8 [PMID: 26340688]
  27. Drug Metab Pers Ther. 2020 Nov 2;: [PMID: 33128525]
  28. Clin Nutr ESPEN. 2021 Jun;43:9-15 [PMID: 34024569]
  29. Metabol Open. 2021 Jun;10:100096 [PMID: 34056571]
  30. Dose Response. 2021 Mar 30;19(1):1559325820982423 [PMID: 33867892]
  31. Lancet Respir Med. 2020 Dec;8(12):1233-1244 [PMID: 33075298]
  32. J Agric Food Chem. 2006 Feb 8;54(3):973-9 [PMID: 16448211]
  33. Thorax. 2021 Feb;76(2):196-200 [PMID: 33323479]
  34. Drug Metab Pers Ther. 2020 Sep 23;: [PMID: 32966232]
  35. Sci Rep. 2018 Nov 16;8(1):16951 [PMID: 30446676]
  36. J Chromatogr A. 1995 May 5;699(1-2):107-18 [PMID: 7757208]
  37. Pharmacogn Mag. 2014 Apr;10(Suppl 2):S419-24 [PMID: 24991121]
  38. Anticancer Agents Med Chem. 2019;19(1):38-47 [PMID: 30599111]
  39. J Diet Suppl. 2011 Mar;8(1):58-114 [PMID: 22432635]
  40. Eur J Pharmacol. 2010 Dec 1;648(1-3):110-6 [PMID: 20854811]
  41. Molecules. 2017 Dec 23;23(1): [PMID: 29295497]

Word Cloud

Created with Highcharts 10.0.0COVID-19cytokineassesssaffronstormactionsSaffronpotentialestudiessaffron'sparticularlycrocinCOVID-19-relatedSARS-CoV-2treatmentclinicalAIM:roledownregulatinginflammationMAINFINDINGS:Threemaincompoundsicrocetinesterspicrocrocinsafranalpresentstrongantioxidantanti-inflammatoryactionseveraldiseasestatesgAlzheimer'scancerdepressionalsostudiedparticularbasedcomprehensivereviewessentialoilsconstituentsappearimmunomodulatoryanti-asthmaticcanhelpfultreatpatientsrespiratorysymptomsdueMoreoverappearsreducecascadedownregulateangiotensin-convertingenzyme2geneexpressionLastsuggestastragalininhibitoryproteasespikeproteinrespectivelyCONCLUSION:representspromisingsubstancetoningwellpreventiveHoweverappropriaterandomizedtrialsespeciallyusingbiomarkerssurrogatesinflammatorystatusdesignedorderefficacyallowuseadjunctmodalityresource-poorsettingsaccessdrugsmaylimitedstorm:Hypehope?mini-reviewcurrentevidenceCytokineInflammationTraditionalmedicine

Similar Articles

Cited By